Pharmaceutical Services M&A Transactions

United Therapeutics acquires Thymmune Therapeutics, enhancing its regenerative medicine and cell therapy capabilities with a $300 million deal including earn-outs.

Caidya

Caidya and Simbec-Orion combine forces, forming a specialized CRO to streamline drug development from early science to global clinical trials.

SteriMax strengthens its Canadian market presence by acquiring Andone Pharmaceuticals, enhancing its healthcare and medical device portfolio. Learn more.

Headlands Research expands its clinical trial network by acquiring Clinical Trials Research, enhancing its capabilities in cardiometabolic and other key therapeutic areas.

Martis Capital takes majority stake in Deerfield Group, a fast-growing healthcare marketing and communications agency. Learn more about the deal.

Ipsen secures Kartos Therapeutics' navtemadlin in a deal up to $1.75B, enhancing its hemato-oncology pipeline with a promising myelofibrosis treatment.

Agilent Technologies completes Biocare Medical acquisition, enhancing its diagnostics and pathology offerings. Learn about the strategic implications.

Boundless Bio

Boundless Bio and Serapha Bio unite in a merger, raising $230 million to pioneer a gene editing therapy for Alpha-1 Antitrypsin Deficiency.

Tredence enhances its healthcare and life sciences analytics services by acquiring KMK Consulting, strengthening its position in a key growth market.

Veeva Systems enhances its life sciences platform with Copli's AI, launching Veeva Falcon MLR to accelerate critical medical, legal, and regulatory content reviews.

Model N strengthens 340B and gross-to-net revenue management with Kalderos acquisition, offering enhanced compliance and revenue reconciliation for life sciences.

AbbVie nears $10.9 billion deal for Apogee Therapeutics, boosting its inflammatory disease pipeline with a long-acting drug candidate. Industry M&A heats up.

Biogen strengthens its immunology pipeline by acquiring RayThera for up to $1 billion, gaining access to promising small-molecule therapies for immune-mediated diseases.

Premier Biotech

Premier Biotech, with Align Capital Partners, acquires NexScreen and TransMed, enhancing its global diagnostics and e-commerce offerings in healthcare and workplace safety.